By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bavarian Nordic A/S 

Vesterbrogade 149

Copenhagen    DK-1620  Denmark
Phone: 45-3326-8383 Fax: 45-3326-8380




Company News
Bavarian Nordic (BAVA.CO) Announces Results Of A Phase 1 Trial Investigating Brachyury Specific Cancer Vaccine In Patients With Advanced Cancers 11/3/2015 10:45:52 AM
Bavarian Nordic (BAVA.CO) Applauds Recommendations Outlined By U.S. Blue Ribbon Study Panel On Biodefense 10/28/2015 12:12:23 PM
Bavarian Nordic (BAVA.CO) Announces Expansion Of IMVAMUNE Orders From Canadian Government 10/28/2015 10:26:16 AM
Bavarian Nordic (BAVA.CO) Announces Initiation Of Safety And Immunogenicity Study Of Ebola Vaccine Regimen In Sierra Leone 10/9/2015 9:56:01 AM
Bavarian Nordic (BAVA.CO) Announces Initiation Of NCI-Sponsored Phase 2 Study Of PROSTVAC In Patients With Localized Prostate Cancer 7/24/2015 10:10:25 AM
Bavarian Nordic (BAVA.CO) Announces That The Oxford Vaccines Group Has Initiated A Phase II Study Of The Ebola Prime-Boost Vaccine Regimen Combining MVA-BN Filo And Janssen's Advac Technology 7/15/2015 9:10:09 AM
Bavarian Nordic (BAVA.CO) Announces Positive Results From Two Pivotal Clinical Studies Of IMVAMUNE Smallpox Vaccine 5/13/2015 9:36:46 AM
Bavarian Nordic (BAVA.CO) Announces Presentation Of Preliminary Phase 1 Results For The Ebola Prime-Boost Vaccine Regimen Of MVA-BN Filo And Janssen Pharmaceutical's AdVac Technology 5/13/2015 9:16:12 AM
Bristol-Myers Squibb (BMY) Bets $975 Million on Bavarian Nordic (BAVA.CO)'s Prostate Cancer Vaccine 3/4/2015 5:34:00 AM
Bavarian Nordic (BAVA.CO) Announces Updated Overall Survival Data From Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The 2015 Genitourinary Cancers Symposium 2/24/2015 10:09:16 AM